Supplemental Digital Content

Table 1. Subject discontinuations and analysis populations

All subjects (N=111)	Month 1	Month 3	Month 6
ITT population (N=83)	83	71	66
PP population (N=55)	55	55	55
Subjects discontinued, n (%)	28 (25.2)	40 (36.0)	45 (40.5)
Subjects remaining in the study, n (%)	83 (74.8)	71 (64.0)	66 (59.5)

The ITT analysis set consisted of subjects who received at least one dose of vortioxetine, and had pre-intervention and at least one post-intervention assessment of efficacy.

The PP analysis set was a subset of the ITT analysis set, and consisted of subjects who completed all scheduled visits without major protocol deviations or violations.

Percentages are based on the total number of enrolled subjects (N=111).

Supplemental Digital Content

Table 2. Adverse drug reactions

Summary of ADRs	**N = 111**	
System Organ Class **Preferred Term**	**n (%) of subjects**	**No. of events**
Any ADRs	**3 (2.7)**	**4**
Serious ADRs		
Not serious		4
Severity		
Mild		4
Changes to study product due to event		
Dose not changed		4
ADRs (diagnosis)		
Nausea	2 (1.8)	2
Gastritis	1 (0.9)	1
Headache	1 (0.9)	1

ADRs were any AEs that were assessed by the investigators to be possibly, probably or definitely related to the study treatment